Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
First Ischemic Stroke in Sickle-Cell Disease: Are There Any Adult Specificities?
source: Stroke
year: 2015
authors: Calvet D, Bernaudin F, Gueguen A, Hosseini H, Habibi A, Galactéros F, Bartolucci P
summary/abstract:BACKGROUND AND PURPOSE:
There is little evidence about characteristics of ischemic stroke (IS) occurring in adults with sickle-cell disease (SCD). The objective of this study was to assess characteristics of first-ever IS in adults with SCD and to assess whether they differ from those occurring in child patients with SCD.
METHODS:
Adult and child individuals with SCD who had a first-ever IS were identified from cohorts of patients followed up in an adult and a child sickle cell referral center. Mechanisms of IS were determined by consensus meeting from all available explorations using the following predefined classification: Vasculopathy, cardioembolism, other defined cause, and undetermined. Treatment and stroke recurrences were recorded from prospective follow-up performed in the referral centers.
RESULTS:
Twenty-nine adults and 26 children had a first-ever IS; mean age (SD) was 7.1 (4.3) and 32.3 (11.6), respectively. With regard to IS mechanism, vasculopathy was less often the cause of IS in adults (12/29, 41%) than in children (24/26, 92%; P<0.001). Other causes of IS in adults were cardioembolism in 7, antiphospholipid syndrome in 1, toxic (cocaine) in 1, and undetermined in 8. Adults with SCD had a higher risk of recurrent stroke (23.1% [7.0-39.2] at 5 years) compared with children (1 recurrence only; P log rank=0.046) despite exchange-blood transfusion in patients with vasculopathy.
CONCLUSIONS:
First-ever IS occurring in adults with SCD has specificities that justify further studies conducted in adults with SCD to improve understanding and management.
DOI: 10.1161/STROKEAHA.115.010153
read more full text
+myBinderRelated Content
-
Sickle Cell Disease: Why Is It Hard to Talk About Our Pain?https://www.youtube.com/watch?v=63pgiclv...
-
Research Team Recognized for Organ-on-a-Chip DesignSCD is a group of genetic disorders that...
-
Inflammatory molecule reduction with hydroxyurea therapy in children with sickle cell anemiaChildren with sickle cell anemia (SCA) s...
-
Orphan Drug Designation Granted for CSL Behring’s Investigational Plasma-Derived Hemopexin Therapy for Sickle ...Global biotherapeutics leader CSL Behrin...
-
Metabolic Syndrome Risk Among Adults Living with Sickle Cell DiseaseBackground: The life span of individuals...
-
Hospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
-
Pregnant Women with Sickle Cell Disease, Especially SS-type, at Risk of ComplicationsWomen with sickle cell disease have a hi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.